Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1

Status

Withdrawn 2

Sponsor Class

OTHER 2

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Lymphoid 1

Conditions

Breast Neoplasms 438Neoplasms 322Carcinoma, Non-Small-Cell Lung 250Prostatic Neoplasms 240Lung Neoplasms 176Colorectal Neoplasms 158Pancreatic Neoplasms 148Neoplasm Metastasis 142Leukemia, Myeloid, Acute 140Multiple Myeloma 131Lymphoma 128Carcinoma, Hepatocellular 127Ovarian Neoplasms 109Melanoma 109Head and Neck Neoplasms 101Brain Neoplasms 101Recurrence 100Leukemia 97Leukemia, Lymphocytic, Chronic, B-Cell 96Precursor Cell Lymphoblastic Leukemia-Lymphoma 90Glioblastoma 85Lymphoma, Non-Hodgkin 83Colonic Neoplasms 79Squamous Cell Carcinoma of Head and Neck 76Lymphoma, Follicular 76Carcinoma, Renal Cell 75Lymphoma, Large B-Cell, Diffuse 71Hematologic Neoplasms 69Sarcoma 60Stomach Neoplasms 58

Interventions

Tetracycline 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Withdrawn × Meibomian Gland Dysfunction × Clear all
NCT01763437 2017-01-12

TET

The Cleveland Clinic

Phase EARLY_PHASE1 Withdrawn

Meibomian Gland Dysfunction, Rosacea, Chalazion

NCT01692665 2014-02-19

Changes of Keratometric Value and Ocular Aberration After Treatment of Meibomian Gland Dysfunction

Yonsei University

Withdrawn
Lymphoid

Meibomian Gland Dysfunction, Lymphoma, Follicular

Data powered by HemOnc (CC BY 4.0) Colophon âš¡